Synergize for Success in HCC: Immunotherapy Advances and the Role of Interventional Radiology

  Рет қаралды 313

PeerView Oncology

PeerView Oncology

7 ай бұрын

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/THZ865. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Lipika Goyal, MD, MPhil, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alentis Therapeutics AG; Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera Biosciences.
Data Safety Monitoring Board for AstraZeneca.
Co-Chair/Planner
Riad Salem, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bard Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai Inc./Merck & Co., Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Пікірлер
The Convergence of Interventional Radiologists and Oncologists in HCC
52:53
小天使和小丑太会演了!#小丑#天使#家庭#搞笑
00:25
家庭搞笑日记
Рет қаралды 42 МЛН
Inside Out 2: ENVY & DISGUST STOLE JOY's DRINKS!!
00:32
AnythingAlexia
Рет қаралды 15 МЛН
How Strong is Tin Foil? 💪
00:26
Preston
Рет қаралды 150 МЛН
Immunotherapy Converts Locally Advanced Hepatocellular Carcinoma into Resectable Disease
1:03:32
NCI Scientific Events and Resources
Рет қаралды 489
Cautious Hope and Optimism in The Age of a Parkinson's Pandemic
56:36
Neurological Foundation of New Zealand
Рет қаралды 4,7 М.
Cancer Immunotherapy Basics: Understand the science behind this cutting-edge treatment
37:26
Making Rounds: Medical Education Documentary Film
1:03:18
Mount Sinai Health System
Рет қаралды 6 МЛН
Stanford Med LIVE: The State of AI in Healthcare and Medicine
58:39
Stanford Medicine
Рет қаралды 19 М.
Elevating Care in Resectable Stage I-III NSCLC
1:03:31
PeerView Oncology
Рет қаралды 272
The Latest in Immunotherapy to Treat Cancer
53:53
UT Southwestern Medical Center
Рет қаралды 28 М.
小天使和小丑太会演了!#小丑#天使#家庭#搞笑
00:25
家庭搞笑日记
Рет қаралды 42 МЛН